Male infertility and semen analysis in ART

February 3, 2026

Agnieszka Popow-Wozniak, PhD, presented findings at Fertility 2026 that explore semen analysis as a strategic infrastructure that enables evidence-based decisions and supports consistency across growing teams. 

One in six people globally experience infertility, with male factors contributing to nearly half of all cases. Semen analysis is the universal first‑line test for the male partner, but its full potential as a standardized foundation for diagnosis, treatment planning, and laboratory quality control may not be fully realized in many programs.2

That gap becomes tangible when we step into a familiar moment in the IVF journey.

Picture this: A couple with no prior IVF attempts has just completed their stimulation cycle, and 12 oocytes are retrieved from the 34-year-old female. She has no tubal issues and a normal hormonal profile. 

But, the semen parameters on the sample obtained from the 36-year-old male are suboptimal. 

Semen Analysis Before vs. After Preparation

  • Concentration: 14 million/mL vs 20 million/mL
  • Motility: 50% vs 90% progressive
  • Morphology: 2% normal form with no known genetic issues

Choosing IVF for borderline cases puts more responsibility on the embryologist’s shoulders. If fertilization fails, the question comes back to you. Clinics often go 100% ICSI because it feels safer.

Ten years ago, said Dr. Popow-Wozniak, this case would be automatic 100% ICSI. Invimed was a small clinic doing just a handful of cycles each month. Semen analysis was simple: concentration, motility, morphology, and then make a decision. 

Patients paid out-of-pocket and costs were high, so the logic was to maximize fertilization chances with the safest choice.

But there exists a biological trade-off. “ICSI does not guarantee fertilization. It bypasses natural sperm-oocyte interaction and skips the natural selection process. IVF, on the other hand, allows that selection to happen – and that can influence embryo quality in ways we’re still learning about,” Dr. Popow-Wozniak explains. 

To help make the decision, Invimed embryologists now use a computer-assisted semen analysis (CASA) system to get objective data behind the decision. Based on CASA analysis, they use 50/50 IVF/ICSI splits for cases like our couple. 

The shift came from having objective data, which enabled:

  • Detailed morphology analysis including head dimensions
  • Supportive vacuole evaluation from captured images, offering indicative morphology insight even whenmotile sperm organelle morphology examination (MSOME) is not performed
  • Traceable raw data (images/videos) that teams can review together when making real-time decisions
  • Progressive tracking across multiple patient cycles for personalized strategies

The team decision-making model: For borderline cases, decisions happen at gamete collection. The embryology team sits together, opens results, and when in doubt, reviews the images. They examine motility percentages and morphology details impossible to capture in manual assessment. This creates collaborative, defensible decision-making.

“Success isn’t just about technology. It’s about responsibility,” said Dr. Popow-Wozniak. “Choosing IVF when possible means respecting natural selection, reducing costs, and following guidelines. And thanks to the tools and training we’ve built, we can make those choices with confidence.”

The confidence to make these borderline decisions didn’t come just from better equipment. Invimed now runs ~4,400 annual cycles per major location. At that volume, informal systems break down.

The solution: Every embryologist at Invimed undergoes independent sperm control assessment annually, earning certification to sign protocols. Across Poland, Invimed now maintains 12 units. All staff work with the same systems daily and validate against the same external benchmark.

Semen analysis is more than checklist before ART. “It’s the foundation of the entire process, from diagnosis to treatment planning, and that strategy often determines whether a patient will return after an unsuccessful first cycle,” said Dr. Popow-Wozniak.

Systems enable confidence. The shift from 100% ICSI to evidence-based splits didn’t come from guideline education. It came from having objective data, validated processes, and traceable decisions teams could review together.

Scale breaks informal systems. Clinics must adapt their workflows as they grow and gain more locations and staff. Standardization requires external validation, not just written protocols.

Most practices will face this inflection point as they scale. Having the right systems in place before volume demands them makes all the difference.

The question for your clinic: How would incorporating computer‑controlled, objective semen analysis (beyond manual, protocol‑based standards) change the decisions you make – and the confidence with which you make them?

Want more insights like this delivered to your inbox?

Sources:

  1. Popow-Wozniak A. Beyond concentration and motility: CASA Standardization as a Key to Smarter ART Decisions. Presented at the 19th Annual Fertility Conference; January, 2026; Edinburgh, Scotland.